Q1 2024 EPS Estimates for bluebird bio, Inc. Raised by Analyst (NASDAQ:BLUE)

bluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Stock analysts at William Blair boosted their Q1 2024 earnings estimates for bluebird bio in a research note issued on Tuesday, March 26th. William Blair analyst S. Corwin now expects that the biotechnology company will post earnings per share of ($0.56) for the quarter, up from their previous estimate of ($0.85). William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for bluebird bio's current full-year earnings is ($1.78) per share. William Blair also issued estimates for bluebird bio's Q2 2024 earnings at ($0.57) EPS, Q3 2024 earnings at ($0.51) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($2.06) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($1.08) EPS.

Several other analysts have also recently weighed in on the stock. Royal Bank of Canada reiterated a "sector perform" rating and issued a $6.00 price target on shares of bluebird bio in a report on Wednesday. Robert W. Baird lowered their price target on bluebird bio from $10.00 to $7.00 and set an "outperform" rating for the company in a research report on Tuesday, December 12th. StockNews.com raised bluebird bio to a "sell" rating in a research report on Thursday. Wedbush reduced their price target on shares of bluebird bio from $1.72 to $1.68 and set a "neutral" rating for the company in a research report on Tuesday, March 19th. Finally, Wells Fargo & Company cut their price objective on bluebird bio from $4.00 to $3.00 and set an "equal weight" rating for the company in a research note on Wednesday. Two analysts have rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $5.87.

bluebird bio Price Performance

NASDAQ:BLUE traded down $0.08 during trading hours on Friday, hitting $1.28. The company had a trading volume of 7,269,558 shares, compared to its average volume of 9,846,197. The company has a market capitalization of $139.96 million, a PE ratio of -1.73 and a beta of 0.75. The stock has a 50-day moving average price of $1.24 and a 200 day moving average price of $2.26. bluebird bio has a 52 week low of $0.88 and a 52 week high of $5.53.

Institutional Trading of bluebird bio

Several hedge funds have recently modified their holdings of the company. US Bancorp DE lifted its position in bluebird bio by 885.7% in the second quarter. US Bancorp DE now owns 7,511 shares of the biotechnology company's stock worth $25,000 after buying an additional 6,749 shares during the last quarter. Raymond James & Associates purchased a new stake in bluebird bio in the 1st quarter valued at about $50,000. Stifel Financial Corp purchased a new stake in bluebird bio in the 3rd quarter valued at about $32,000. Penserra Capital Management LLC bought a new stake in shares of bluebird bio in the 1st quarter valued at about $53,000. Finally, Aigen Investment Management LP bought a new stake in shares of bluebird bio in the 3rd quarter valued at about $34,000. 87.43% of the stock is owned by hedge funds and other institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.